![]() |
|
|
Vol. 284, Issue 1, 142-150, 1998
Service de Biologie Cellulaire (S.P., P.R.), Centre d'Etudes
Nucléaires de Saclay, CEA, Gif-sur-Yvette, France;
Laboratoire de
Spectromètrie de Masse, The potent anticancer drug cis-diamminedichloroplatinum
(II) (cDDP) impairs glucose reabsorption by renal proximal tubular cells, which leads to glucosuria. We investigated the direct effect of
cDDP (0.04-2 mM) on the Na+/glucose cotransport system in
brush-border membrane (BBM) vesicles from the rabbit renal cortex. cDDP
induced 1) concentration-dependent inhibition of the
Na+/glucose cotransport system, by decreasing its
Vmax value and, to a lesser extent, its
affinity, and 2) platinum binding to BBM vesicles, associated with
decreases in protein-bound thiols. cDDP produced weaker inhibition of
the Na+/glucose cotransport system and platinum binding to
BBM vesicles than did highly reactive cDDP hydrated derivatives, with
similar decreases in protein-bound thiols. Treatment with
diethyldithiocarbamic acid (a drug protecting against cDDP
nephrotoxicity), immediately after cDDP exposure, 1) partially lifted
the cDDP-induced inhibition of the Na+/glucose
cotransporter, 2) reduced platinum binding to BBM vesicles, but 3) did
not modify the cDDP-induced decrease in protein-bound thiols. Our
findings strongly suggest that cDDP-induced inhibition of the
Na+/glucose cotransport system is mainly mediated by direct
chemical binding of cDDP and/or its hydrated derivatives to essential
sulfhydryl groups of the transport protein and may also involve other
nucleophilic groups (e.g., the -SCH3 group
of methionines).
0022-3565/98/2841-0142$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics